ADPT

SEC source: 0001209191-20-053371 · doc4.xml · nonDerivative · entry 3

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-20-053371 · doc4.xml · nonDerivative · entry 2

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,209

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-20-053371 · doc4.xml · nonDerivative · entry 1

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-20-053370 · doc4.xml · derivative · entry 4

DOBMEIER ERIC · CIK 0001202785 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 10,000 shares

Expires 2026-10-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-053370 · doc4.xml · nonDerivative · entry 3

DOBMEIER ERIC · CIK 0001202785 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $49.00 to 49.34, inclusive.

SEC source: 0001209191-20-053370 · doc4.xml · nonDerivative · entry 2

DOBMEIER ERIC · CIK 0001202785 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 776

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.155 to 48.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-053370 · doc4.xml · nonDerivative · entry 1

DOBMEIER ERIC · CIK 0001202785 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2020.

SEC source: 0001209191-20-052782 · doc4.xml · derivative · entry 5

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,740

Underlying: Common Stock · 1,900 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F4 · derivative.exercise_date: The options are fully vested and exercisable.

SEC source: 0001209191-20-052782 · doc4.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,778,180

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $50.01 to 50.30, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-052782 · doc4.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,780,080

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-052783 · doc4.xml · derivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,725

Underlying: Common Stock · 80,000 shares

Expires 2024-03-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019.

F2 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-052783 · doc4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019.

SEC source: 0001209191-20-052783 · doc4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019.

SEC source: 0001209191-20-052781 · doc4.xml · derivative · entry 3

BALDO LANCE · CIK 0001780773 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 25,000 shares

Expires 2029-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-052781 · doc4.xml · nonDerivative · entry 2

BALDO LANCE · CIK 0001780773 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020.

SEC source: 0001209191-20-052781 · doc4.xml · nonDerivative · entry 1

BALDO LANCE · CIK 0001780773 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020.

SEC source: 0001209191-20-052780 · doc4.xml · derivative · entry 3

BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 10,000 shares

Expires 2024-10-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019.

F2 · derivative.exercise_date: All options are fully exercisable.

SEC source: 0001209191-20-052780 · doc4.xml · nonDerivative · entry 2

BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019.

SEC source: 0001209191-20-052780 · doc4.xml · nonDerivative · entry 1

BOBULSKY SUSAN · CIK 0001820885 · SVP, Diagnostics, clonoSEQ

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2019.

SEC source: 0001209191-20-052036 · doc4.xml · derivative · entry 12

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300,300

Underlying: Common Stock · 11,100 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-052036 · doc4.xml · nonDerivative · entry 9

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 679

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.86 to 48.17, inclusive.

SEC source: 0001209191-20-052036 · doc4.xml · nonDerivative · entry 8

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,579

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.79 to 47.78, inclusive.

SEC source: 0001209191-20-052036 · doc4.xml · nonDerivative · entry 7

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,139

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.74 to 46.73, inclusive.

SEC source: 0001209191-20-052036 · doc4.xml · nonDerivative · entry 6

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-052268 · doc4.xml · derivative · entry 6

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,875

Underlying: Common Stock · 1,771 shares

Expires 2028-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-052268 · doc4.xml · derivative · entry 5

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,145

Underlying: Common Stock · 1,109 shares

Expires 2029-04-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-052268 · doc4.xml · nonDerivative · entry 4

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,300

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.03 to 48.69, inclusive.

SEC source: 0001209191-20-052268 · doc4.xml · nonDerivative · entry 3

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,896

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.31 to 47.93, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-052268 · doc4.xml · nonDerivative · entry 2

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,180

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-052268 · doc4.xml · nonDerivative · entry 1

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,409

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-052036 · doc4.xml · derivative · entry 11

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 311,400

Underlying: Common Stock · 11,100 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-052036 · doc4.xml · nonDerivative · entry 5

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 679

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.76 to 48.50, inclusive.

SEC source: 0001209191-20-052036 · doc4.xml · nonDerivative · entry 4

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-052036 · doc4.xml · derivative · entry 10

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 322,500

Underlying: Common Stock · 11,100 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-20-052036 · doc4.xml · nonDerivative · entry 3

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 679

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $47.70 to 48.23, inclusive.

SEC source: 0001209191-20-052036 · doc4.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,779

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.71 to 47.68, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-20-052036 · doc4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,779

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-051733 · doc4.xml · derivative · entry 3

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,917

Underlying: Common Stock · 417 shares

Expires 2027-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-20-051733 · doc4.xml · nonDerivative · entry 2

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-20-051733 · doc4.xml · nonDerivative · entry 1

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 417

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-20-051235 · doc4.xml · derivative · entry 14

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,640

Underlying: Common Stock · 16,680 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F10 · derivative.exercise_date: The options are fully vested and exercisable.

SEC source: 0001209191-20-051235 · doc4.xml · nonDerivative · entry 11

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,778,180

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F9 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $45.80 to 46.55, inclusive.

SEC source: 0001209191-20-051235 · doc4.xml · nonDerivative · entry 10

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,786,760

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $44.79 to 45.74, inclusive.

SEC source: 0001209191-20-051235 · doc4.xml · nonDerivative · entry 9

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,794,860

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-051235 · doc4.xml · derivative · entry 13

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 211,320

Underlying: Common Stock · 16,680 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F10 · derivative.exercise_date: The options are fully vested and exercisable.

SEC source: 0001209191-20-051235 · doc4.xml · nonDerivative · entry 8

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,778,180

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $44.58 to 45.57, inclusive.

SEC source: 0001209191-20-051235 · doc4.xml · nonDerivative · entry 7

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,792,260

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $44.35 to 44.57, inclusive.

SEC source: 0001209191-20-051235 · doc4.xml · nonDerivative · entry 6

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,794,860

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

SEC source: 0001209191-20-051235 · doc4.xml · derivative · entry 12

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,000

Underlying: Common Stock · 16,680 shares

Expires 2021-12-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F10 · derivative.exercise_date: The options are fully vested and exercisable.

SEC source: 0001209191-20-051235 · doc4.xml · nonDerivative · entry 5

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,778,180

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.26 to 48.27, inclusive.